Company: CERO
Filing Date: 2025-01-07
Form Type: 424B3
Source: 0001213900-25-001661
Chunk: 5

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-07
Form: 424B3
Chunk 5
---
holders held on November 11, 2024 (the “Special Meeting”), and upon the recommendation
of the Company’s Board of Directors (the “Board”), the Company’s stockholders approved a certificate of amendment
to effect a reverse stock split of the Common Stock at a ratio ranging from any whole number between 1-for-25 and 1-for-150, as determined
by the Board in its discretion, subject to the Board’s authority to abandon such amendment (the “Charter Amendment”).

The Charter Amendment was
described in detail under “Proposal No. 1: Reverse Stock Split Proposal” beginning on page 10 of the Company’s definitive
proxy statement filed with the Securities and Exchange Commission on October 15, 2024 (the “Proxy Statement”) in connection
with the Annual Meeting. The text of the Charter Amendment was included in Appendix A of the Proxy Statement.

On December 25, 2024, the
Board approved a reverse stock split of the Common Stock at a ratio of 1-for-100. Effective as of 12:01 a.m. Eastern Time on January 8,
2025, the Company filed the Charter Amendment and effected a 1-for-100 reverse stock split of its shares of Common Stock (the “Reverse
Stock Split”).

As a result of the Reverse
Stock Split, every 100 shares of the Company’s Common Stock issued or outstanding were automatically reclassified into one validly
issued, fully-paid and non-assessable new share of Common Stock, subject to the treatment of fractional shares as described below, without
any action on the part of the holders. Proportional adjustments were made to the number of shares of Common Stock awarded and available
for issuance under the Company’s equity incentive plans, as well as the exercise price and the number of shares issuable upon the
exercise or conversion of the Company’s outstanding stock options and other equity securities under the Company’s equity incentive
plans. Additionally, all outstanding shares of preferred stock were adjusted in accordance with their terms, which resulted, among other
changes to the preferred stock terms, in proportionate adjustments being made to the number of shares issuable upon exercise of such preferred
stock and to the conversion prices of such preferred stock. All outstanding warrants were also adjusted in accordance with their terms,
which resulted, among other changes to the warrant terms, in proportionate adjustments being made to the number of shares issuable upon
exercise of such warrants and to the exercise and redemption prices of such